Halozyme Therapeutics (HALO) PT Raised to $48 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $127.22 -1.09%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Join SI Premium – FREE
JMP Securities analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $48.00 (from $45.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Fortune Brands (FBIN) PT Lowered to $58 at DA Davidson
- Cinemark Holdings (CNK) PT Raised to $45 at StoneX
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
